Healthcare Industry News: Artisan Extend
News Release - May 3, 2010
Hansen Medical and Siemens Announce Agreement to Co-Develop Integrated Products to Advance Treatment of Irregular HeartbeatsMOUNTAIN VIEW, CA., May 3--(HSMN NewsFeed) - Hansen Medical, Inc. (NASDAQ:HNSN ) and Siemens Healthcare today announced joint development and cooperation agreements to co-develop integrated products designed to help simplify complex cardiac procedures for the diagnosis and treatment of cardiac arrhythmias, or irregular heartbeats.
Cardiac arrhythmias can drastically reduce the quality of life and can also lead to serious health risks including heart failure and stroke. Nearly 550,000 new patients are diagnosed with cardiac arrhythmias in the United States each year, and arrhythmias cause approximately 250,000 deaths annually according to the Heart Rhythm Foundation and the American College of Cardiology. The condition also affects over 4.5 million people in Europe.
"For Siemens Healthcare, the joint development and cooperation agreement with Hansen Medical is another important step towards integrated solutions advancing the quality of care for an increased number of patients," said Dr. Heinrich Kolem, CEO Angio-, Fluoroscopic- & Radiographic Systems for Siemens. "We believe the combination of our efforts will enable us to offer our customers significant improvements in workflow during the treatment of cardiac arrhythmias."
The Sensei X system is the next generation flexible robotic platform that integrates advanced levels of 3D catheter control with 3D visualization. This innovative technology is designed to provide fine catheter control while mapping in 3D to enhance the physician's ability to access hard-to-reach cardiac anatomy and maintain stability during complex cardiac arrhythmia procedures.
Siemens' Artis zee systems including Artis zeego, the first multi-axis system based on robotic technology, are ideal for cardiac diagnostics and interventions, even hybrid procedures. The flexible and ergonomic design enables clinicians to optimally adapt the system configuration to focus on interventional cardiology, pediatric and electrophysiology applications with tableside operation. In addition, the syngo DynaCT Cardiac enables CT-like imaging of the heart with an angiocardiographic system during cardiac procedures, so that physicians can visualize the left atrium and pulmonary veins in 3D.
"Hansen Medical is committed to improving the clinical experience of electrophysiologists worldwide, and we are extremely pleased to be collaborating with Siemens Healthcare to develop integrated products that offer comprehensive solutions," said Frederic Moll, M.D., CEO, Hansen Medical. "These joint agreements will allow both companies to offer enhanced procedural planning and workflow, as well as improved capabilities to customers. The design of our integrated solution will improve visualization and instinctive driving within 3D anatomical models, resulting in improved catheter navigation and contact while inside a patient's heart."
The Sensei X platform is built upon an open architecture design and Hansen Medical's commitment to open architecture allows for successful collaboration with a broad range of leading imaging companies.
About Hansen Medical, Inc. Hansen Medical Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the SenseiŽ Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and was cleared by the U.S. Food and Drug Administration (FDA) in May 2007 for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. The Sensei system is CE Marked for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements This press release contains forward-looking statements that involve risks, uncertainties, assumptions, and other factors, which, if they do not materialize or prove correct, could cause Hansen Medical's results to differ materially from those expressed or implied, by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including, statements containing the words "plan," "expects," "believes," "goal," "estimate," "may" and similar words. Hansen Medical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, product development risks, potential safety and regulatory issues that could delay approvals, and the scope and validity of intellectual property rights applicable to products being developed. These and other risks are described in greater detail under the heading "Risk Factors" contained in our periodic SEC filings.
Hansen Medical, Heart Design, Hansen Medical & Heart Design, Sensei, IntelliSense and Fine Force Technology are registered trademarks, and Artisan, Artisan Extend, Lynx, CoHesion and Instinctive Motion are trademarks of Hansen Medical Inc., in the United States and other countries.
Artis zee and syngo are registered trademarks of Siemens AG.
Source: Hansen Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.